Global Myocardial Infarction Drugs Market 2016-2020

2016-03-08
Price :
Published : Mar-2016
No. of Pages : 75

Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.

The analysts forecast global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Myocardial Infarction Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Bayer HealthCare
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi

Other prominent vendors

  • advanceCOR
  • Armaron Bio
  • Athersys
  • BioVascular
  • BMS
  • Caladrius
  • Capricor
  • CSL Behring
  • GNT Pharma
  • GSK
  • Ischemix
  • Mesoblast
  • NeuroVive
  • Osiris Therapeutics
  • PledPharma
  • RegeneRx
  • Teva Pharmaceuticals
  • TiGenix
  • US Stem Cell
  • Ventrix

Market driver

  • Growing older population
  • For a full, detailed list, view our report

Market challenge

  • Alternative therapies
  • For a full, detailed list, view our report

Market trend

  • Growing awareness of disease
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026

EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026 Summary GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development. In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes ......
$3995

EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2026

EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2026 Summary Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE (AHA, 2017). Our epidemiologists forecast an increase in the diagnosed inciden......
$3995

Chlamydia Tests – Medical Devices Pipeline Assessment, 2017

Chlamydia Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData's Medical Devices sector report, "Chlamydia Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Chlamydia Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Chlamydia Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team o......
$2500

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2016. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the......
$3500

Top Trends in Healthcare and OTC 2017: Exploring OTC medication, vitamins, minerals and supplements; functional food and drink; and sports nutrition categories

Global consumers are becoming more health-conscious as a reaction to rising obesity levels and lifestyle-related illnesses, such as diabetes, in the modern world. Consumers' busy lives are a major driver for the healthcare and OTC market as people opt for more convenient, multifunctional, and personalized products that better target their specific needs. Over-the-counter (OTC) drugs are those sold directly to a consumer without a prescription from a healthcare professional, as compared to prescription drugs, which may be sold only to consumers possessing a valid prescription. The pressures of modern life are taking their toll on consumers as their increasingly hectic lifestyles, due to work, active social lives and family responsibilities, means that stress is the most concerning hea......
$3450

Underground Gas Storage Industry Outlook in North America to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites

Underground Gas Storage Industry Outlook in North America to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites Summary "Underground Gas Storage Industry Outlook in North America to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Storage Sites", is a comprehensive report on underground gas storage industry in North America. The report provides gas storage site details such as asset name, operator name, storage type, start year, working gas capacity along with withdrawal rate for all active and planned gas storage assets in the region. The report also provides key country comparisons based on contribution to working gas capacity. The report also provides capital expenditure outlook by key coun......
$5000

Underground Gas Storage Industry Outlook In Former Soviet Union To 2021: Capacity And Capital Expenditure Forecasts With Details Of All Operating And Planned Storage Sites

Underground Gas Storage Industry Outlook In Former Soviet Union To 2021: Capacity And Capital Expenditure Forecasts With Details Of All Operating And Planned Storage Sites Summary "Underground Gas Storage Industry Outlook In Former Soviet Union To 2021: Capacity And Capital Expenditure Forecasts With Details Of All Operating And Planned Storage Sites", is a comprehensive report on underground gas storage industry in Former Soviet Union. The report provides gas storage site details such as asset name, operator name, storage type, start year, working gas capacity along with withdrawal rate for all active and planned gas storage assets in the region. The report also provides key country comparisons based on contribution to working gas capacity. The report also provides capital expenditure o......
$5000

Gas Processing Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Processing Plants

Gas Processing Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Processing Plants Summary "Gas Processing Industry Outlook in Europe to 2021: Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Processing Plants", is a comprehensive report on gas processing industry in Europe. The report provides gas processing plant details such as name, operator name, type, start year, process/conditioning methods and gas processing capacity for active and planned gas processing plants in the region. The report also provides key country comparisons based on contribution to processing capacity. The report also provides capital expenditure outlook by key countries, year on year, from 2017 to 2021. Pla......
$5000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Germany

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany Summary Germany has a mature healthcare market based on its high healthcare expenditure and pharmaceutical production. The increasingly elderly population and its associated disease burden are expected to drive the growth of the pharmaceutical market, while government initiatives to reduce healthcare expenditure will limit growth. The value of the German pharmaceuticals market increased from EUR37.3 Billion (US$54.7 Billion) in 2008 to EUR43.3 Billion (US$57.6 Billion) in 2013 at a Compound Annual Growth Rate (CAGR) of 1.0%. In US dollar terms, the market declined from US$54.7 Billion in 2008 to US$51.2 Billion in 2012 at a negative CAGR of 1.7% due to frequent currency devaluation. The value of the pharmaceutica......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data prese......
$1000